T he vascular endothelial growth factor (VEGF) family of vascular growth factors in mammals is composed of 5 proteins (VEGFs A-D) and of a closely related placenta growth factor. VEGFs act by binding to 3 closely related receptor tyrosine kinases (VEGFR1-3) and 2 nonkinase receptors, neuropilin (NRP) 1 and 2.
1 Specificity of the biological activity of various VEGFs is determined, in part, by preferential binding of certain VEGFs to specific VEGFRs. Thus, VEGF-A and -B and placenta growth factor bind to VEGFR1, VEGF-A, and -C to VEGFR2, and VEGF-C and -D predominantly bind to VEGFR3. 2 Specificity is further determined by differential expression of VEGF receptors, with VEGFR1 and VEGFR2 being the predominant isoforms in blood endothelial cells (EC). VEGFR3 is initially expressed during early embryonic development by both blood and lymphatic endothelial cells (LECs) later on becoming largely restricted to LECs. 3 However, its expression can be reinduced in blood ECs during angiogenesis, 4 and it may play an important role in retinal blood vasculature formation. 5 VEGFR3 is also found in non-ECs, including neuronal progenitors, macrophages, and osteoblasts. 2 VEGFR2 signaling has been extensively studied as a prototype VEGF receptor. Recent advances include the appreciation of its interaction with vascular endothelial (VE)-cadherin, 6 neuropilin 1, 7 various phosphotyrosine phosphatases (PTPs), including density-enhanced phosphatase-1, 8 vascular endothelial phosphotyrosine phosphatase (VE-PTP), 9 and PTP1B, 7, 10 as well as the role of its endocytosis in the extracellular signal-regulated kinases (ERK) cascade activation. 6, 11 In contrast, relatively little is known about molecular controls of VEGFR3 signaling, although some details of VEGFR2 phosphorylation in blood ECs have been reported. 12 Previous studies demonstrated that when bound by their ligands, both VEGFR2 and VEGFR3 form homodimers and undergo autophosphorylation of cytoplasmic tyrosine residues, leading to activation of their kinase activity. In addition to forming homodimers, on VEGF-C or VEGF-A stimulation, VEGFR3 can also form complexes with VEGFR2. 13, 14 Interestingly, VEGF-C-induced complexes concentrate on the leading edge of LECs, suggesting their involvement in cell migration. Yet the relative contribution of VEGFR3 homodimers versus VEGFR3/R2 complexes to activation of various intracellular signaling pathways and LECs biology has not been established.
VEGFR signaling also involves coreceptor proteins neuropilin 1 and neuropilin 2. 15 These transmembrane proteins are able to bind both VEGFs and semaphorins and regulate vascular and neural development. 16 In the vascular system, neuropilin 1 is largely expressed in the arterial endothelium and lymphatic vessel valves, whereas neuropilin 2 is the predominant neuropilin in venous and lymphatic ECs. 17 During lymphatic vessel development, neuropilin 1 acts as a semaphorin receptor in the valve endothelium, 17 whereas neuropilin 2 is involved in VEGF-C-driven lymphatic vessel growth. 18 Despite these phenotypic observations, specific contributions of neuropilin 1 and neuropilin 2 to VEGF-C/VEGFR3 signaling have not been defined.
Recent studies have also highlighted the importance of PTPs in regulating VEGF receptor signaling. In the case of VEGFR2, these involve PTP1B, 10, 11 VE-PTP, 9, 19 and CD148/ density-enhanced phosphatase-1. 8 In contrast, PTPs involvement in VEGFR3 signaling has not been defined. A PTP nonreceptor type 14 has recently been shown to be involved in lymphatic development, but its role in VEGFR3 signaling is not established. 20 In the present study, we set out to study VEGFR3 signaling in human dermal lymphatic endothelial cells (HDLECs). To this end, we examined VEGF-C versus VEGF-A-dependent activation of ERK1/2 and protein kinase B (AKT) signaling and examined the contribution of key signaling proteins, including VEGFR2 and R3, neuropilin 1 and neuropilin 2, and various PTPs. We find that VEGFR2 and neuropilin 1 are required for VEGF-C-induced AKT activation. Moreover, we found that VE-PTP, but not other phosphatases, is able to modulate VEGFR3 activation. Finally, we determined that VEGF-C stimulation of LEC migration requires activation of both ERK and AKT pathways.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Molecular Differences in VEGFR3 Versus VEGFR2 Signaling in the Lymphatic Endothelium
To examine the differences in VEGFR3-versus VEGFR2-induced activation of key endothelial signaling pathways, such as ERK and AKT, we compared the effect of VEGF-A versus VEGF-C stimulation of HDLECs that express both VEGFR2 and VEGFR3. Stimulation with VEGF-A resulted in a strong and rapid (within 5 minutes) activation of ERK1/2 pathway and a relatively mild activation of phosphoinositide 3-kinase signaling as determined by AKT phosphorylation ( Figure 1A and 1B). In contrast, when stimulated with VEGF-C, both ERK and AKT were activated with a much slower kinetics, but the extent of AKT activation was far greater than seen with VEGF-A ( Figure 1A and 1B). These findings are in agreement with a previous in vitro study of VEGF-C signaling. 21 We next asked whether VEGFR3 signaling shares some of the key molecular elements involved in regulation of VEGFR2 signaling, such as synectin (an adaptor protein which is critical to VEGFR2 trafficking and VEGF-A-induced ERK activation) and PTP1B (an intracellular protein tyrosine phosphatase that has been shown to colocalize to VEGFR2 early endosomes and regulate its activation of ERK1/2). 22 A knockdown of either synectin or PTP1b had no effect on VEGF-C-induced ERK or AKT activation in HDLEC ( Figure IA and IB in the onlineonly Data Supplement). Moreover, VEGF-C failed to induce PTP1B colocalization with internalized VEGFR3 ( Figure IC in the online-only Data Supplement).
VEGFR3 has previously been reported to form complexes with VEGFR2 on VEGF-C stimulation in cultured LEC and tip cells in vivo. 13, 14 However, whether such complex formation affects VEGFR3 endocytosis and signaling has not been defined. To determine the role of VEGFR2 in these processes, we examined formation of VEGFR2/R3 complexes after VEGF-C and VEGF-A stimulation. In agreement with previous studies, VEGFR2 coimmunoprecipitated with VEGFR3 in HDLECs that were stimulated by VEGF-C, whereas only marginal VEGFR2/R3 coimmunoprecipitation was observed after VEGF-A treatment ( Figure 1C ). This was confirmed using confocal microscopy analysis of endocytosed receptors after VEGF-A or VEGF-C stimulation. Treatment of HDLEC with VEGF-C induced both VEGFR3 and VEGFR2 internalization and a significant degree of colocalization between the 2 receptors ( Figure 1D and 1F). In contrast, VEGF-A induced strong VEGFR2, but only marginal VEGFR3 internalization and a much lesser extent of colocalization of the 2 receptors was observed ( Figure 1E and 1F).
VEGFR2 Is Involved in VEGFR3 Endocytosis and AKT Activation
To examine the contribution of VEGFR2 to VEGFR3 signaling, we used VEGFR2 siRNA to knockdown its expression in HDLEC. Reduction in VEGFR2 expression significantly impaired VEGF-C-induced AKT activation, but surprisingly had no effect on ERK activation (Figure 2A and 2B). It also did not affect VEGF-C-induced VEGFR3 internalization ( Figure 2C ).
Phosphorylation of VEGFR2 at Y 1175 is crucial for activation of both ERK1/2 and AKT by the receptor. Similar to VEGF-A, VEGF-C was also able to induce VEGFR2 Y 1175 phosphorylation in HDLEC ( Figure 2D ). However, the extent of VEGF-C-induced phosphorylation was much weaker and the kinetics slower than that by VEGF-A ( Figure 2E ). To determine whether VEGFR2 kinase activity is required for VEGFR3 signaling, we expressed either a control (wildtype) or a dominant-negative kinase-dead VEGFR2 mutant (K868R) construct 23 Data Supplement). The expression of the mutant receptor had no effect on VEGF-C-induced ERK or AKT activation ( Figure 2F ) or formation of VEGFR2/R3 complexes ( Figure 2G ), indicating that VEGFR2 kinase activity is dispensable for VEGFR3 signaling.
Neuropilin 1 but not Neuropilin 2 Is Involved in VEGFR3 Signaling in Lymphatic Endothelial Cells
Besides VEGFR2, neuropilin 2, highly expressed in lymphatic and venous ECs, is thought to play a role in VEGFR3
signaling. In addition, neuropilin 1, although predominantly found in arterial ECs, is also expressed in a portion of lymphatic ECs. Therefore, we next set out to examine the roles of neuropilin 1 and neuropilin 2 in VEGF-C signaling in HDLECs. We first tested whether the 2 neuropilins interact with VEGFR3 on VEGF-C stimulation. Neuropilin 2 but not neuropilin 1 could be immunoprecipitated with VEGFR3 after VEGF-C stimulation ( Figure 3A and 3B) . However, although a knockdown of neuropilin 2 expression had no effect on Figure 1 . Comparison of vascular endothelial growth factor receptor 2 (VEGFR2) and VEGFR3 signaling. A, Serum-starved human dermal lymphatic endothelial cells (HDLECs) were stimulated with VEGF-C (100 ng/mL) or VEGF-A (50 ng/mL) and activation of extracellular signal-regulated kinases (ERK)1/2 and protein kinase B (AKT) was determined by Western blotting. B, Quantitative analyses of ERK and AKT phosphorylation in panel A normalized to total ERK and AKT levels, respectively. Data represent mean±SEM of 3 independent experiments. C, Serum-starved HDLECs were stimulated with 100 ng/mL VEGF-C or 50 ng/mL VEGF-A for the indicated length of time. VEGFR3 immunoprecipitate was then probed with anti-VEGFR2 antibody (upper panel). Lower panel, Western blot analysis of total cell lysates corresponding to the upper panel. D-E, Serum-starved HDLECs were incubated with anti-VEGFR3 and VEGFR2 antibodies and then stimulated with 100 ng/mL VEGF-C (D) or 50 ng/mL VEGF-A (E) for the indicated length of time. Internalized VEGFR3 (red) and VEGFR2 (green) were visualized by confocal microscopy. Early endosome was labeled with anti-early endosome antigen 1 (EEA1; D, blue) and nuclear with DAPI (E, blue). F, Co-localization of VEGFR3 with VEGFR2 was quantified using Pearson's statistics. At least 6 fields of >20 cells were used for quantification. Statistical analysis was performed using 2-way analysis of variance. February 2015 VEGF-C-induced ERK or AKT activation ( Figure 3C and 3D), neuropilin 1 knockdown severely impaired VEGF-C-induced AKT but not ERK activation ( Figure 3C and 3E) , thus resembling the effect of VEGFR2 knockdown. Knocking down both neuropilin 1 and neuropilin 2 had a similar effect on VEGFR3 signaling to that observed with a single neuropilin 1 knockdown, indicating that neuropilin 1 but not neuropilin 2 plays a predominant role in regulating VEGF-C signaling ( Figure 3C ).
To determine whether either neuropilin is involved in VEGF-C-induced VEGFR3 internalization, we followed the fate of surface biotinylated VEGFR3 after VEGF-C Figure 3 . Neuropilin 1 but not neuropilin 2 is required for vascular endothelial growth factor (VEGF)-C signaling. A and B, Serum-starved human dermal lymphatic endothelial cells (HDLECs) were stimulated with 100 ng/mL VEGF-C and then subjected to Western blotting with anti-neuropilin 2 (A) or neuropilin 1 (B) antibodies of VEGFR3 antibody immunoprecipitates (upper panels). Lower panels, Western blotting of whole cell lysates. C, HDLECs transfected with neuropilin 1, neuropilin 2, or control siRNAs were serum-starved and stimulated with 100 ng/mL VEGF-C. Activation of VEGFR3 signaling was examined by Western blotting as indicated. D and E, Quantification of extracellular signal-regulated kinases (ERK) and protein kinase B (AKT) phosphorylation after neuropilin 2 (D) or neuropilin 1 (E) knockdowns. Data represents Mean±SEM of 3 independent experiments. Statistical analysis was performed using 2-way ANOVA. F and G, VEGF-C-induced VEGFR3 internalization after neuropilin 2 (F) or neuropilin 1 (G) knocked down and control HDLECs was determined by serial Western blotting of cell lysates after cell surface biotinylation as described in Methods Figure 3F and 3G. Note that 20% of lane S sample was loaded. Data in G is a summary of the quantification and represented mean±SEM of ≥3 independent experiments. Statistical analysis was performed using 2-way analysis of variance. H, Serum-starved HDLECs treated with anti-VE-PTP or control siRNAs were stimulated with 100 ng/mL VEGF-C followed by Western blotting with anti-VEGFR2 antibody of VEGFR3 immunoprecipiates. VEGFR3/VEGFR2 interaction was determined by IP using antibodies against VEGFR3 and Western blot.
VE-PTP Regulates VEGF-C/VEGFR3 Signaling
To determine whether a protein tyrosine phosphatase is involved in regulation of VEGFR3 signaling, we knocked down PTPs expressed in LEC and observed the effect of these knockdowns on VEGF-C-dependent activation of ERK and AKT activation. Although knockdowns of PTP1B, PTPu, Src homology region 2 domain-containing phosphatase-1, and density-enhanced phosphatase-1 did not show any significant effect on VEGF-C-induced ERK and AKT activation, a VE-PTP knockdown significantly activated these pathways ( Figure IVA and IVB in the online-only Data Supplement; Figure 4A and 4B). In agreement with a previously established role of VE-PTP in regulation of VEGFR2 phosphorylation, 9, 19 the activation of this receptor, as judged by Y 1175 phosphorylation, was also increased (Figure 4A and 4B) .
To find out whether VE-PTP regulates VEGFR3 phosphorylation, we performed phosphotyrosine blotting of immunoprecipitated VEGFR3 after VEGF-C stimulation from HDLEC treated with VE-PTP or control siRNA sequences. VE-PTP knockdown resulted in a nearly 6-fold increase in VEGFR3 tyrosine phosphorylation compared with control knockdown ( Figure 4C and 4D) . To further confirm the interaction between these 2 molecules, we next examined the presence of VE-PTP in VEGFR3 immunoprecipitate. Although essentially no VE-PTP was present before VEGF-C treatment, there was a marked increase in its presence after VEGF-C exposure ( Figure 4E) .
The presence of VE-PTP in fact also has a significant effect on VEGFR3 internalization. Using a cell surface biotinylation assay, we observed a significant increase in VEGF-C-induced VEGFR3 internalization after siRNA VE-PTP knockdown ( Figure 4F and 4G) . However, VE-PTP is not involved in VEGFR2/VEGFR3 interaction because knocking down VE-PTP had no effect on the kinetics or extent of complex formation ( Figure 4H ).
VEGFR2 and Neuropilin 1 Are Required for VEGF-C-Induced Cell Migration
Having established roles played by NRPs, VE-PTP, and VEGFR2 in VEGFR3 signaling, we next examined the effect of these signaling changes on LEC migration using a wound healing assay. Knockdown of VEGFR2 and neuropilin 1 abolished cell migration of HDLEC in response to VEGF-C, whereas knocking down VE-PTP strikingly showed no effect ( Figure 5A ). In agreement with the minor role played by neuropilin 2 in VEGFR3-dependent ERK and AKT activation, its knockdown had only a marginal effect on VEGF-C-induced migration ( Figure 5A) .
To compare the role of the same proteins in VEGF-A signaling, we examined the effect of their knockdown on VEGF-A-induced HDLEC migration. As expected, knockdown of VEGFR2 completely abolished VEGF-A-induced cell migration ( Figure 5B ). However, we did not observe any significant effect of neuropilin 1 knockdown on VEGF-A-induced cell migration, indicating that neuropilin 1 plays a distinct role in VEGF-C versus VEGF-A-induced cell migration. Similar to our observation in VEGF-C-induced cell migration, knockdown of neuropilin 2 and VE-PTP did not show any effect on the ability of HDLEC to migrate in response to VEGF-A, indicating that both of the 2 molecules are likely dispensable for these processes. Finally, we investigated the importance of ERK and AKT activation in VEGF-C-versus VEGF-Ainduced cell migration. Inhibition of either ERK or AKT suppressed VEGF-C-induced cell migration, whereas only ERK but not AKT inhibition suppressed VEGF-A-induced cell migration ( Figure 5C and 5D ).
Discussion
The results of this study define relative contributions of various VEGFR3 partners to VEGF-C-induced signaling in LECs. In particular, we find that although VEGFR3/VEGFR2 complex formation is critical to VEGF-C-induced AKT activation, ERK activation by this growth factor is primarily driven by VEGFR3 homodimer. Furthermore, although neuropilin 1 plays an essential role in AKT activation, it is dispensable for ERK activation. At the same time, a plasma membrane protein VE-PTP acts as a VEGFR3 tyrosine phosphatase and modulates both ERK and AKT activation by VEGF-C. Functionally, both ERK and AKT pathways play an equally important role in regulating LEC migration ( Figure 5E ).
One unexpected finding is the role of VEGFR2/R3 complex in VEGF-C-driven AKT activation. The role of VEGFR2 in this complex is apparently to bring in its partner neuropilin 1. This is suggested by the fact that VEGFR2 kinase activity is not required for either the complex formation or AKT activation, as well as by the observed decrease in AKT activation after neuropilin 1 knockdown. The fact that NRP1 was not detected on co-IP with VEGFR2 is likely attributable to low levels of this protein in LECs. The function of neuropilin 1 in this setting is distinctly different from the role it plays in VEGFR2-driven ERK activation, where it is involved in intracellular trafficking of VEGFR2. 7 How neuropilin 1 facilitates AKT activation in the case of VEGFR3/R2 complex is not known.
Taken together with the observation that knockdown of VEGFR2 and neuropilin 1 did not affect VEGFR3 endocytosis and ERK activation but specifically abolished AKT activation, our data argues that VEGFR3-driven ERK but not AKT activation is dependent on receptor endocytosis. Although this endocytosis dependence of VEGFR3/ERK signaling is similar to that of VEGFR2 activation of ERK, 22 in the distinction to the latter, VEGFR3 intracellular signaling does not seem affected by its subsequent intracellular trafficking because neither an intracellular phosphatase PTP1b nor synectin, regulators of VEGFR2 trafficking, affected this pathway. These findings are further in agreement with recent in vivo demonstration of the role of VEGFR2 in lymphatic vessel morphogenesis. 24 The other key finding is the role of VE-PTP in modulating VEGFR3 signaling. VE-PTP knockdown enhanced both ERK and AKT activation. The effect of VE-PTP is likely attributable to a direct dephosphorylation of VEGF-C-activated VEGFR3 on the plasma cell membrane, thus diminishing ERK and AKT activation. Although VEGFR3/VE-PTP complexes have not been previously reported, we observed coimmunoprecipitation of the 2 proteins after, but not before, VEGF-C treatment of HDLECs. An unexpected finding is that VE-PTP knockdown does not increase HDLEC migration above baseline. This is likely because migration is already fully activated by the normal VEGF signaling.
Another unexpected finding is the lack of significant contribution of neuropilin 2 to VEGFR3 signaling, despite its role in lymphatic biology. 18 The 2 proteins do form a complex as suggested by immunoprecipitation experiments, 25 but there seems to be little effect from neuropilin 2 knockdown on either VEGF-C-driven ERK and AKT activation or LEC migration. This may reflect intrinsic limitations of an in vitro study, although it should be noted that there is no clear data supporting or refuting neuropilin 2 contributions to lymphatics biology in vivo. In addition, AKT activation in this study was dispensable for VEGF-A-induced LEC migration, though a previous report suggested its involvement in this process. 24 The reason for this difference is not clear. In summary, these studies have uncovered novel feature of VEGFR3 lymphatic endothelium signaling involving regulation of AKT activation via VEGFR3/VEGFR2/neuropilin 1 complex, ERK via VEGFR3/R3 homodimer, as well as regulatory roles of VE-PTP.
Lymphatic endothelial cells play a key biological role in many disease processes. Yet our knowledge of how signal transduction takes place in this cell type is incomplete. The principle signaling receptors in the lymphatic endothelium are vascular endothelial growth factor (VEGF) receptor 2 and 3. In this study, we investigated how these receptors transmit signal from VEGF-C, the growth factor responsible for much of the lymphatic biology. We find that VEGFR3 homodimer activates extracellular signal-regulated kinases-1/2 pathway, whereas VEGFR2/ R3 complex activates protein kinase B signaling. Furthermore, VEGFR3-driven extracellular signal-regulated kinases but not protein kinase B activation is dependent on the receptor endocytosis, whereas activation of both pathways is modulated by a transmembrane phosphatase vascular endothelial phosphotyrosine phosphatase.
Significance
